Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Brazil’s ANVISA Globalizes on Class I/II Medtech Regs, Hikes Fees

This article was originally published in Clinica

Executive Summary

New medical technology resolutions issued by Brazil’s healthcare products regulatory agency, ANVISA, are designed to help both the regulator and medtech manufacturers, in terms of simplified processes and speed to market.

You may also be interested in...



Brazil Gives Medtech More Time to Deal With Technical Dossier Rule

Anvisa has extended the deadline for companies to prepare technical dossiers for low-risk medical devices and in vitro diagnostics, giving industry more time to deal with the costs and work involved with complying with the new requirement.

UK MHRA Updates Assistive Tech And Borderline Regulations

Device classification themes were uppermost in April for the UK regulator, which issued key guidance in two areas prone to complexities. It also contributed to the MedTech Directorate’s one-year progress report.

Helping Organizations Deliver On KPIs And Giving Staff A Voice

ImproveWell has won awards for its software technology that allows health care staff at the sharp end of patient care to report on problems as they happen. The outcome is a real-time learning process that contributes to improved operational efficiencies for health systems, says In Vivo Rising Leader Lara Mott.

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

MT102934

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel